Active ingredient
- tenofovir alafenamide fumarate
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 11972/0024.
Vemlidy 25 mg film coated tablets
Package leaflet: Information for the patient
Vemlidy 25 mg film-coated tablets
tenofovir alafenamide
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What Vemlidy is and what it is used for
2. What you need to know before you take Vemlidy
3. How to take Vemlidy
4. Possible side effects
5. How to store Vemlidy
6. Contents of the pack and other information
1. What Vemlidy is and what it is used for
Vemlidy contains the active substance tenofovir alafenamide. This is an antiviral medicine, known as a nucleotide reverse transcriptase inhibitor (NtRTI).
Vemlidy is used to treat chronic (long-term) hepatitis B in adults and adolescents 12 years of age and older, who weigh at least 35 kg. Hepatitis B is an infection affecting the liver, caused by the hepatitis B virus. In patients with hepatitis B, Vemlidy controls the infection by stopping the virus from multiplying.
2. What you need to know before you take Vemlidy
Do not take Vemlidy
Warnings and precautions
Children and adolescents
Do not give this medicine to children who are under 12 years old or weigh less than 35 kg. Vemlidy has not been tested in children aged less than 12 years old or weighing less than 35 kg.
Other medicines and Vemlidy
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Vemlidy may interact with other medicines. As a result, the amounts of Vemlidy or other medicines in your blood may change. This may stop your medicines from working properly, or may make any side effects worse.
Medicines used in treating hepatitis B infection
Do not take Vemlidy with other medicines containing:
Other types of medicines
Talk to your doctor if you are taking:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Vemlidy can cause dizziness. If you feel dizzy when taking Vemlidy, do not drive and do not use any tools or machines.
Vemlidy contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Vemlidy contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
3. How to take Vemlidy
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is one tablet once a day with food. Treatment should continue for as long as your doctor tells you. Usually this is for at least 6 to 12 months and may be for many years.
If you take more Vemlidy than you should
If you accidentally take more than the recommended dose of Vemlidy you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects).
Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.
If you forget to take Vemlidy
It is important not to miss a dose of Vemlidy. If you do miss a dose, work out how long since you should have taken it.
If you are sick (vomit) less than 1 hour after taking Vemlidy, take another tablet. You do not need to take another tablet if you are sick (vomit) more than 1 hour after taking Vemlidy.
If you stop taking Vemlidy
Do not stop taking Vemlidy without your doctor’s advice. Stopping treatment with Vemlidy may cause your hepatitis B to get worse. In some patients with advanced liver disease or cirrhosis, this could be life-threatening. If you stop taking Vemlidy, you will need regular health checks and blood tests for several months to check your hepatitis B infection.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common side effects
(may affect more than 1 in 10 people)
Common side effects
(may affect up to 1 in 10 people)
Uncommon side effects
(may affect up to 1 in 100 people)
Tests may also show:
During HBV therapy there may be an increase in weight, fasting levels of blood lipids and/or glucose. Your doctor will test for these changes.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the
or search for MHRA Yellow Card in the Google Play or Apple App Store
By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Vemlidy
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}. The expiry date refers to the last day of that month.
Store in the original package in order to protect from moisture. Keep the bottle tightly closed.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Vemlidy contains
The active substance is tenofovir alafenamide. Each Vemlidy film-coated tablet contains tenofovir alafenamide fumarate, equivalent to 25 mg of tenofovir alafenamide.
The other ingredients are
Tablet core:
Lactose monohydrate, microcrystalline cellulose (E460(i)), croscarmellose sodium (E468), magnesium stearate (E470b).
Film-coating:
Polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol (E1521), talc (E553b), iron oxide yellow (E172).
What Vemlidy looks like and contents of the pack
Vemlidy film-coated tablets are yellow, round, printed (or marked) with “GSI” on one side of the tablet and “25” on the other side of the tablet. Vemlidy comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets). The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets. Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in 01/2021.
280 High Holborn, London, WC1V 7EE, UK
+353 214 825 999 (Ireland)
+44 (0)203 681 4681
+44 (0)203 681 4500
08000 113 700 (UK)
+353 1 291 3580 (Ireland)